Results 211 to 220 of about 98,783 (260)

Nephroprotective Potential of Olea europaea Leaf Extract Against Combined Noise and Toluene‐Induced Oxidative and Histopathological Renal Injuries in Wistar Rats

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT Noise and toluene are environmental stressors that induce oxidative stress and inflammation, contributing to renal dysfunction. This study evaluated the protective effects of Olea europaea leaf extract (OeLE; 40 mg/kg/day) against combined noise‐ and toluene‐induced nephrotoxicity in Wistar rats.
Takoua Ben Attia   +6 more
wiley   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft   +6 more
wiley   +1 more source

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen   +10 more
wiley   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito   +9 more
wiley   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu   +3 more
wiley   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin   +3 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy